Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.085 USD | +1.15% | +1.48% | -26.72% |
Jan. 05 | CureVac Reports Positive Phase 2 Results for mRNA Covid Vaccines Developed With GSK | MT |
Jan. 05 | GSK, CureVac Plan Late-stage Study of COVID-19 mRNA Vaccine Candidates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.72% | 683M | |
+9.11% | 45.97B | |
+52.56% | 43.93B | |
+7.25% | 42.34B | |
-8.78% | 28.27B | |
+18.29% | 27.18B | |
-20.89% | 19.44B | |
+14.75% | 13.83B | |
+31.90% | 12.4B | |
+8.60% | 11.45B |
- Stock
- Equities
- Stock CureVac N.V. - Nasdaq
- News CureVac N.V.
- CureVac Reports Narrower Q2 Loss